Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

The settlement agreement allows Alvotech and its commercial partners to market and sell the biosimilar as of January 1, 2026 in the United Kingdom and Canada, as well as in Japan (excluding the ...

Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar

Alvotech (ALVO) has reached a licensing and settlement agreement with Regeneron (REGN) and Bayer (BAYZF), resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea ...
Business Insider

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

REYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, ...
Nasdaq

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ...
The Daily Reflector

UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06,

REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...
Seeking Alpha

Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)

REYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Nasdaq

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today ...

Alvotech: Why FDA Delays Don't Break The Bull Case

Alvotech has five approved drugs, including biosimilars of AbbVie's Humira, Johnson & Johnson's Stelara/Simponi, and Eylea. See why ALVO stock is a Strong Buy.
Eagle-Tribune

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed ...

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...
Hosted on MSN

Alvotech Faces FDA Setback for AVT05 Biosimilar Application

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alvotech ( (ALVO)) has issued an update.
WGHP

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
The Bakersfield Californian

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

Agne Pasko joined Alvotech in 2019, and has held several senior roles in Commercial Operations, Supply Chain and Business Development, driving revenue growth, new partnerships and portfolio expansion.